Sanofi Launches Generic Eloxatin Injection

Share this content:
Sanofi announced the launch of Oxaliplatin Injection, the generic version of its Eloxatin.
Sanofi announced the launch of Oxaliplatin Injection, the generic version of its Eloxatin.

Sanofi announced the launch of Oxaliplatin Injection, the generic version of its Eloxatin, through the company's generic division Winthrop US.

Oxaliplatin, an alkylating agent, is indicated for adjuvant treatment for stage III colon cancer in patients who have undergone complete resection of the primary tumor (in combination with infusional 5-FU/LV), and for treatment of advanced colorectal cancer (in combination with infusional 5-FU/LV).

RELATED: Colon Cancer Treatment Regimens

Oxaliplatin undergoes nonenzymatic conversion in physiologic solutions to active derivatives via displacement of the labile oxalate ligand. Several transient reactive species are formed, including monoaquo and diaquo DACH platinum, which covalently bind with macromolecules. Both inter- and intrastrand Pt-DNA crosslinks are formed. These crosslinks inhibit DNA replication and transcription.

Oxaliplatin Injection is available in 50mg and 100mg single-use vials.

For more information call (800) 981-2491 or visit WinthropUS.com.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs